See What HealthDay Can Do For You
Contact Us

SABCS: T-DM1 Cuts Recurrent Invasive HER2+ Breast CA Risk

Risk reduced with trastuzumab emtansine in those with residual invasive dz at sx after neoadjuvant chemo

syringe

WEDNESDAY, Dec. 5, 2018 (HealthDay News) -- For patients with residual invasive disease after neoadjuvant chemotherapy including a taxane and trastuzumab, substituting trastuzumab emtansine (T-DM1) for adjuvant trastuzumab is associated with a reduced risk for invasive recurrence of human epidermal growth factor receptor 2 (HER2)-positive primary breast cancer, according to a study presented at the annual San Antonio Breast Cancer Symposium, held from Dec. 4 to 8 in Texas.

Charles E. Geyer Jr., M.D., from the Virginia Commonwealth University Massey Cancer Center in Richmond, and colleagues conducted a phase III, open-label, global study of patients with centrally confirmed HER2-positive primary breast cancer who received neoadjuvant chemotherapy including a taxane and trastuzumab followed by surgery. Patients had pathologically documented residual invasive disease in the breast and/or axillary lymph nodes. They were randomly assigned in a 1:1 ratio to receive T-DM1 or trastuzumab for 14 cycles.

After approximately 67 percent of the invasive disease-free survival (IDFS) events required for the primary analysis had occurred, a single interim analysis was conducted. After review of this analysis, full analysis and disclosure of the results was recommended. The researchers found that administration of T-DM1 significantly improved IDFS compared with trastuzumab with 256 events reported (unstratified hazard ratio, 0.50).

"The results should form the foundation of a new standard of care in patients with residual invasive breast cancer following neoadjuvant therapy," Geyer said in a statement.

One author disclosed financial ties to F. Hoffmann La Roche/Genentech, which manufactures trastuzumab emtansine and supported the study.

Press Release
More Information

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.